Om

Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Melbourne, Australia, focused on developing targeted biologic therapies for serious diseases. The company specializes in vascular endothelial growth factor (VEGF) biology and related pathways, applying this expertise to conditions driven by abnormal blood and lymphatic vessel growth and function. Ceryvyn Therapeutics’ current activities center on lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that predominantly affects women, where it is advancing CYV-101, a fusion protein designed to modulate the dysregulated biology underlying the condition. By leveraging prior late-stage clinical experience with this molecule, the company aims to efficiently generate robust clinical data in LAM. Operating within the biotechnology and medical research sector, Ceryvyn Therapeutics serves the broader healthcare market by pursuing therapies intended for high unmet-need indications, with development spanning Australia and the United States. Founded in 1984 and headquartered in Melbourne, it functions as a specialized player in rare disease and VEGF-targeted drug development.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I CERYVYN THERAPEUTICS MED ENDAVU: Køb Ceryvyn Therapeutics ($UKJ0) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Ceryvyn Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.